The U.S. Dialysis Market is expected to grow considerably through 2032 owing to the surging prevalence of diabetes in the U.S. given a drastic change in lifestyle.

Growing incidences of chronic diseases, scientific and technical breakthroughs in dialysis in the United States, an aging population, as well as rising demand for at-home dialysis are some of the key factors expected to drive industry growth. Additionally, rising disposable income and higher healthcare costs are anticipated to improve the U.S. dialysis industry outlook.

Leading market players are investing in R&D initiatives to develop breakthrough technologies to improve the quality of patient care. For instance, in March 2021, Baxter received U.S. FDA approval in March 2021 for its AK98 (Artificial kidney 98) dialysis machine. The device is meant to be employed for intermittent hemodialysis as well as isolated ultrafiltration therapies for individuals with acute or chronic fluid overload or renal failure. The move is likely to bolster the company’s prominence in the market.

The U.S. dialysis market has been divided in terms of type, application, end-use, and zone.

Based on type, peritoneal dialysis is anticipated to expand through the forecast timeline due to the increasing use of innovative and technically advanced devices during medical procedures. Moreover, peritoneal dialysis boasts of several benefits over hemodialysis, including fewer dietary restrictions, more freedom over lifestyle choices, and no need for frequent hospital visits.

With respect to application, the consumables segment held more than USD 5.8 billion in revenue in 2022 credited to the rising requirement for dialysis therapy as a form of kidney disease treatment. The market expansion is expedited by developments in consumables including catheters, which guarantee effective therapy. The use of dialysis therapy will increase demand for the supplies needed for the operation, fueling segmental growth.

In terms of end-use, the home dialysis segment is poised to grow significantly over the review years attributed to the several advantages it offers, including better quality of life, lower travel costs, flexibility, and simple patient mobility, leading to a rise in its adoption.

Based on zone, the Pacific Central dialysis market is speculated to grow at more than 3.5% CAGR from 2023 to 2032 driven by the massive disease burden in the region, rising privatization, rising health insurance penetration, aggravating efforts to increase the number of qualified health care personnel, and the rapidly aging population susceptible to several chronic illnesses.